Cancer Letters
Volume 238, Issue 2 , Pages 161-167 , 18 July 2006

The roles of Chk 1 and Chk 2 in hypoxia and reoxygenation

  • Ester M. Hammond
    • ,
  • Rachel A. Freiberg
    • ,
  • Amato J. Giaccia

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Stanford University School of Medicine, Radiation Oncology, CCSR South Room 1250, 269 Campus Drive, Stanford CA 94305, USA. Tel.: +1 650 725 6418; fax: +1 650 723 7382.

Received 3 June 2005 ,Accepted 15 June 2005.

References 

  1. Hockel M, Knoop C, Schlenger K, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 1993;26:45–50
  2. Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. Adv. Exp. Med. Biol. 345 (1994) 445–450.
  3. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer. Res. 1996;56:4509–4515
  4. Hockel M, Schlenger K, Doctrow S, Kissel T, Vaupel P. Therapeutic angiogenesis. Arch. Surg. 1993;128:423–429
  5. Hockel M, Schlenger K, Hockel S, et al. Tumor hypoxia in pelvic recurrences of cervical cancer. Int. J. Cancer. 1998;79:365–369
  6. Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer. Res. 1999;59:4525–4528
  7. Bindra RS, Schaffer PJ, Meng A, et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol. Cell Biol. 2004;24:8504–8518
  8. Bindra RS, Glazer PM. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat. Res. 2005;569:75–85
  9. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer. Res. 1998;58:1408–1416
  10. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer. 2004;4:437–447
  11. Hammond EM, Giaccia AJ. The role of ATM and ATR in the cellular response to hypoxia and re-oxygenation. DNA Repair (Amst). 2004;3:1117–1122
  12. Hammond EM, Dorie MJ, Giaccia AJ. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J. Biol. Chem. 2003;278:12207–12213
  13. Canman CE, Lim DS. The role of ATM in DNA damage responses and cancer. Oncogene. 1998;17:3301–3308
  14. Kastan MB, Lim DS. The many substrates and functions of ATM. Nat. Rev. Mol. Cell Biol. 2000;1:179–186
  15. Brown EJ, Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev. 2003;17:615–628
  16. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14 (2000) 397–402.
  17. Koumenis C, Alarcon R, Hammond E, et al. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol. Cell Biol. 2001;21:1297–1310
  18. Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ. Hypoxia links ATR and p53 through replication arrest. Mol. Cell Biol. 2002;22:1834–1843
  19. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999;286:2528–2531
  20. Lee SB, Kim SH, Bell DW, et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res. 2001;61:8062–8067
  21. Vahteristo P, Tamminen A, Karvinen P, et al. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: Further evidence of CHK2 in inherited cancer predisposition. Cancer Res. 2001;61:5718–5722
  22. Hirao A, Kong YY, Matsuoka S, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 2000;287:1824–1827
  23. Jallepalli PV, Lengauer C, Vogelstein B, Bunz F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J. Biol. Chem. 2003;
  24. Adamson AW, Beardsley DI, Kim WJ, et al. Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol. Biol. Cell. 2005;16:1513–1526
  25. Singh SV, Herman-Antosiewicz A, Singh AV, et al. Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J. Biol. Chem. 2004;279:25813–25822
  26. Xu B, Kim ST, Lim DS, Kastan MB. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol. Cell Biol. 2002;22:1049–1059
  27. Canman CE, Kastan MB. Small contribution of G1 checkpoint control manipulation to modulation of p53-mediated apoptosis. Oncogene. 1998;16:957–966
  28. Tercero JA, Longhese MP, Diffley JF. A central role for DNA replication forks in checkpoint activation and response. Mol. Cell. 2003;11:1323–1336
  29. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 2004;3:513–519
  30. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat. Rev. Cancer. 2004;4:216–225
  31. Hammond EM, Dorie MJ, Giaccia AJ. Inhibition of ATR Leads to Increased Sensitivity to hypoxia/reoxygenation. Cancer Res. 2004;64:6556–6562
  32. Lopes M, Cotta-Ramusino C, Pellicioli A, et al. The DNA replication checkpoint response stabilizes stalled replication forks. Nature. 2001;412:557–561
  33. Casper AM, Nghiem P, Arlt MF, Glover TW. ATR regulates fragile site stability. Cell. 2002;111:779–789
  34. Syljuasen RG, Sorensen CS, Nylandsted J, et al. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing radiation. Cancer Res. 2004;64:9035–9040
  35. Sorensen CS, Syljuasen RG, Falck J, et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell. 2003;3:247–258
  36. Syljuasen RG, Sorensen CS, Hansen LT, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell Biol. 2005;25:3553–3562
  37. Sorensen CS, Hansen LT, Dziegielewski J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell Biol. 2005;7:195–201
  38. Heffernan TP, Simpson DA, Frank AR, et al. An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation following UVC-induced DNA damage. Mol. Cell Biol. 2002;22:8552–8561
  39. Sonoda E, Sasaki MS, Buerstedde JM, et al. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. Embo. J. 1998;17:598–608
  40. Green SL, Freiberg RA, Giaccia AJ. p21 (Cip 1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol. Cell Biol. 2001;21:1196–1206
  41. Lundin C, Erixon K, Arnaudeau C, et al. Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells. Mol. Cell Biol. 2002;22:5869–5878
  42. Tauchi H, Kobayashi J, Morishima K, et al. Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells. Nature. 2002;420:93–98
  43. Hammond EM, Green SL, Giaccia AJ. Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest. Mutat. Res. 2003;532:205–213
  44. Venkitaraman AR. Medicine: Aborting the birth of cancer. Nature. 2005;434:829–830
  45. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907–913
  46. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–870
  47. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432:316–323
  48. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379:88–91
  49. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol. Cell Biol. 1994;14:1669–1679
  50. Shimada K, Pasero P, Gasser SM. ORC and the intra-S-phase checkpoint: a threshold regulates Rad53p activation in S phase. Genes Dev. 2002;16:3236–3252
  51. Vafa O, Wade M, Kern S, et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol. Cell. 2002;9:1031–1044
  52. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA–ssDNA complexes. Science. 2003;300:1542–1548
  53. Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: Partners in checkpoint signaling. Science. 2001;294:1713–1716
  54. Cimprich KA. Fragile sites: Breaking up over a slowdown. Curr. Biol. 2003;13:R231–R233
  55. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell Biol. 2001;21:4129–4139
  56. Shiloh YATM. and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003;3:155–168

PII: S0304-3835(05)00566-5

doi: 10.1016/j.canlet.2005.06.029

Cancer Letters
Volume 238, Issue 2 , Pages 161-167 , 18 July 2006

Article Tools

* Image Usage & Resolution